Rosenthal N - Search Results

1

Alveolar macrophage surface carbohydrate expression is altered in interstitial lung disease as determined by lectin-binding profiles.

Meyer KC, Powers C, Rosenthal N, Auerbach R. Meyer KC, et al. Among authors: rosenthal n. Am Rev Respir Dis. 1993 Nov;148(5):1325-34. doi: 10.1164/ajrccm/148.5.1325. Am Rev Respir Dis. 1993. PMID: 8239171

2

Tryptophan metabolism in chronic inflammatory lung disease.

Meyer KC, Arend RA, Kalayoglu MV, Rosenthal NS, Byrne GI, Brown RR. Meyer KC, et al. Among authors: rosenthal ns. J Lab Clin Med. 1995 Dec;126(6):530-40. J Lab Clin Med. 1995. PMID: 7490512

3

Immune dysregulation in the aging human lung.

Meyer KC, Ershler W, Rosenthal NS, Lu XG, Peterson K. Meyer KC, et al. Among authors: rosenthal ns. Am J Respir Crit Care Med. 1996 Mar;153(3):1072-9. doi: 10.1164/ajrccm.153.3.8630547. Am J Respir Crit Care Med. 1996. PMID: 8630547

4

Degradation of annexin I in bronchoalveolar lavage fluid from patients with cystic fibrosis.

Tsao FH, Meyer KC, Chen X, Rosenthal NS, Hu J. Tsao FH, et al. Among authors: rosenthal ns. Am J Respir Cell Mol Biol. 1998 Jan;18(1):120-8. doi: 10.1165/ajrcmb.18.1.2808. Am J Respir Cell Mol Biol. 1998. PMID: 9448053

5

Neutrophils and low-grade inflammation in the seemingly normal aging human lung.

Meyer KC, Rosenthal NS, Soergel P, Peterson K. Meyer KC, et al. Among authors: rosenthal ns. Mech Ageing Dev. 1998 Aug 14;104(2):169-81. doi: 10.1016/s0047-6374(98)00065-7. Mech Ageing Dev. 1998. PMID: 9792195

6

Transient decrease in IL-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients.

Weil-Hillman G, Hank JA, Rosenthal NS, Sondel PM. Weil-Hillman G, et al. Among authors: rosenthal ns. J Biol Response Mod. 1988 Oct;7(5):424-37. J Biol Response Mod. 1988. PMID: 3053997

7

In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

Hank JA, Kohler PC, Weil-Hillman G, Rosenthal N, Moore KH, Storer B, Minkoff D, Bradshaw J, Bechhofer R, Sondel PM. Hank JA, et al. Among authors: rosenthal n. Cancer Res. 1988 Apr 1;48(7):1965-71. Cancer Res. 1988. PMID: 3258180

8

The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.

Rosenthal NS, Hank JA, Kohler PC, Minkoff DZ, Moore KH, Bechhofer R, Hong R, Storer B, Sondel PM. Rosenthal NS, et al. J Biol Response Mod. 1988 Apr;7(2):123-39. J Biol Response Mod. 1988. PMID: 3258904

9

Clinical testing of IL-2: in vivo administration of IL-2 induces IL-2 dependent non-MHC-restricted cytotoxicity (NRC).

Sondel PM, Hank JA, Rosenthal N, Moore KH, Hong R, Storer B, Kohler PC. Sondel PM, et al. Among authors: rosenthal n. Prog Clin Biol Res. 1987;244:173-84. Prog Clin Biol Res. 1987. PMID: 3498947 No abstract available.

10

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

Sondel PM, Kohler PC, Hank JA, Moore KH, Rosenthal NS, Sosman JA, Bechhofer R, Storer B. Sondel PM, et al. Among authors: rosenthal ns. Cancer Res. 1988 May 1;48(9):2561-7. Cancer Res. 1988. PMID: 3258545

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

710 results

Search Page

Filters